Spies, M
Kraus, C
Geissberger, N
Auer, B
Klöbl, M
Tik, M
Stürkat, I-L
Hahn, A
Woletz, M
Pfabigan, D M
Kasper, S
Lamm, C
Windischberger, C
Lanzenberger, R
Article History
Received: 13 July 2016
Revised: 11 October 2016
Accepted: 13 November 2016
First Online: 24 January 2017
Competing interests
: MS has received travel grants from AOP Orphan Pharmaceuticals AG, Janssen-Cilag Pharma and Eli Lilly, workshop participation from Eli Lilly and speaker honoraria from Janssen-Cilag Pharma. CK has received travel grants from Roche Austria and AOP Orphan Pharmaceuticals AG. SK has received grant/research support from Eli Lilly, Lundbeck A/S, Bristol-Myers Squibb, Servier, Sepracor, GlaxoSmithKline, Organon and Dr Willmar Schwabe, has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, German Research Foundation (DFG), GlaxoSmithKline, Eli Lily, Lundbeck A/S, Pfizer, Organon, Sepracor, Janssen-Cilag Pharma and Novartis and has served on speakers’ bureaus for AstraZeneca, Eli Lilly, Lundbeck A/S, Servier, Sepracor and Janssen-Cilag Pharma. RL received travel grants and conference speaker honoraria from AstraZeneca, Lundbeck A/S, Roche Austria, Dr Willmar Schwabe, AOP Orphan Pharmaceuticals AG and Janssen-Cilag Pharma. The remaining authors declare no conflict of interest.